JP2016033133A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016033133A5 JP2016033133A5 JP2015159977A JP2015159977A JP2016033133A5 JP 2016033133 A5 JP2016033133 A5 JP 2016033133A5 JP 2015159977 A JP2015159977 A JP 2015159977A JP 2015159977 A JP2015159977 A JP 2015159977A JP 2016033133 A5 JP2016033133 A5 JP 2016033133A5
- Authority
- JP
- Japan
- Prior art keywords
- granulated product
- preparation
- uncoated tablet
- pharmaceutically acceptable
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 claims 7
- 238000000034 method Methods 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 4
- 229960005127 montelukast Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 238000005550 wet granulation Methods 0.000 claims 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- 239000011247 coating layer Substances 0.000 claims 2
- 229960001951 montelukast sodium Drugs 0.000 claims 2
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 claims 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 238000004040 coloring Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015159977A JP6575031B2 (ja) | 2014-07-28 | 2015-07-28 | モンテルカストナトリウム製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014153305 | 2014-07-28 | ||
| JP2014153305 | 2014-07-28 | ||
| JP2015159977A JP6575031B2 (ja) | 2014-07-28 | 2015-07-28 | モンテルカストナトリウム製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019122670A Division JP7093752B2 (ja) | 2014-07-28 | 2019-07-01 | モンテルカストナトリウム製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016033133A JP2016033133A (ja) | 2016-03-10 |
| JP2016033133A5 true JP2016033133A5 (enrdf_load_stackoverflow) | 2018-08-02 |
| JP6575031B2 JP6575031B2 (ja) | 2019-09-18 |
Family
ID=55452210
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015159977A Active JP6575031B2 (ja) | 2014-07-28 | 2015-07-28 | モンテルカストナトリウム製剤 |
| JP2019122670A Active JP7093752B2 (ja) | 2014-07-28 | 2019-07-01 | モンテルカストナトリウム製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019122670A Active JP7093752B2 (ja) | 2014-07-28 | 2019-07-01 | モンテルカストナトリウム製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP6575031B2 (enrdf_load_stackoverflow) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017001989A (ja) * | 2015-06-11 | 2017-01-05 | ニプロ株式会社 | 医薬組成物の製造方法及び医薬組成物 |
| CN108057021B (zh) * | 2017-12-25 | 2019-03-19 | 南京康舟医药科技有限公司 | 一种孟鲁斯特钠颗粒剂及其制备方法 |
| JPWO2020111089A1 (ja) * | 2018-11-27 | 2021-10-14 | 協和キリン株式会社 | 医薬組成物 |
| CN112386578B (zh) * | 2020-10-26 | 2022-11-22 | 石药集团欧意药业有限公司 | 一种孟鲁司特钠咀嚼片及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090124657A1 (en) | 2007-08-14 | 2009-05-14 | Ramesh Kappala | Pharmaceutical compositions comprising montelukast |
| WO2009153305A2 (en) | 2008-06-19 | 2009-12-23 | Sandoz Ag | Pharmaceutical compositions of montelukast sodium |
| US20110189274A1 (en) | 2008-10-06 | 2011-08-04 | Swati Mukherjee | Stable Pharmaceutical Compositions Of Montelukast Or Its Salts Or Solvates Or Hydrates |
| KR20130009553A (ko) * | 2011-07-15 | 2013-01-23 | 한미약품 주식회사 | 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제 |
| KR101418404B1 (ko) * | 2012-01-06 | 2014-07-10 | 한미약품 주식회사 | 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제 |
| CN103239450B (zh) | 2012-02-07 | 2014-11-26 | 齐鲁制药有限公司 | 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法 |
| JP5858486B2 (ja) * | 2012-05-11 | 2016-02-10 | 塩野義製薬株式会社 | アスコルビン酸、スクラロースおよびアスパルテームを含有する固形製剤 |
| CN103494785B (zh) | 2013-10-09 | 2015-03-11 | 福建华海药业有限公司 | 一种孟鲁司特钠咀嚼片及其制备方法 |
-
2015
- 2015-07-28 JP JP2015159977A patent/JP6575031B2/ja active Active
-
2019
- 2019-07-01 JP JP2019122670A patent/JP7093752B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518337A5 (enrdf_load_stackoverflow) | ||
| NZ705578A (en) | Coated pharmaceutical composition containing regorafenib | |
| JP2016033133A5 (enrdf_load_stackoverflow) | ||
| MY196243A (en) | Dihydropyrimidine Compounds and Their Application In Pharmaceuticals | |
| JP2017039724A5 (enrdf_load_stackoverflow) | ||
| IL311677B1 (en) | History of bicyclic heterocyclyls as IRAK4 inhibitors | |
| MX394584B (es) | Preparación que comprende vonoprazán. | |
| MX389304B (es) | Producto farmaceutico. | |
| EP3412292B8 (en) | Use of methoxatin, derivative and/or salt thereof in sjogren's syndrome and pharmaceutical composition | |
| EP3312175A4 (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| HK1256256A1 (zh) | 包含urat1的有效抑制剂的药物组合物 | |
| EP3453703A4 (en) | CRYSTALLINE FORM OF TAFAMIDIS-METHYLGLUCAMINE SALT AND MANUFACTURING METHOD AND APPLICATION THEREOF | |
| HK1244429A1 (zh) | 特别用於治疗注意力缺陷障碍的方法和组合物 | |
| WO2014204881A8 (en) | Delayed release cysteamine bead formulation | |
| JP2016532632A5 (enrdf_load_stackoverflow) | ||
| WO2017103600A8 (en) | Preparation of respirable zafirlukast particles | |
| FI3248597T3 (fi) | Terapeuttinen aine sensorineuraaliseen kuulonmenetykseen | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| EP3648745A4 (en) | PHARMACEUTICAL COMPOSITION WITH SPHERICAL TABLET OF MULTIPLE UNITS WITH AMEOMEPRAZOLE AND SPHERICAL PHARMACEUTICAL SALT THEREOF AND METHOD FOR MANUFACTURING THE PHARMACEUTICAL COMPOSITION | |
| EP3898582A4 (en) | NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY APPROVED SALT THEREOF, COMPOSITION THEREOF, AND METHODS OF USE THEREOF | |
| PH12019500638A1 (en) | Composite formed into single layer, comprising candesartan and amlodipine | |
| CO2018002046A2 (es) | Nueva composición oral de libreación retardada dual de dexlansoprazol | |
| HUE055530T2 (hu) | 7H-pirrolo[2,3-D]pirimidin vegyület kristály formája és só formája, és ezek elkészítési eljárása | |
| JP2015129124A5 (enrdf_load_stackoverflow) | ||
| JP2016013980A5 (enrdf_load_stackoverflow) |